ARID1B: A Promising Drug Target and Potential Biomarker for Multiple Chronic Diseases

Target Name: ARID1B

NCBI ID: G57492

ARID1B

ARID1B: A Promising Drug Target and Potential Biomarker for Multiple Chronic Diseases

ARID1B (AT-rich interactive domain-containing protein 1B isoform 1) is a protein that has recently been identified as a potential drug target and biomarker for a range of chronic diseases. Its unique structure and function have made it an attractive target for researchers to investigate, and its potential as a drug or biomarker has significant implications for the treatment of such diseases. In this article, we will explore the biology and potential applications of ARID1B, including its structure, function, and potential as a drug target and biomarker.

Structure and Function

The structure of ARID1B is unique, as it consists of a combination of domains including an N-terminal transmembrane domain, a coiled-coil domain, and a C-terminal T-loop domain. The N-terminal transmembrane domain is responsible for the protein's ability to interact with various cell signaling pathways, including the TGF-β pathway. The coiled-coil domain is responsible for the protein's ability to adopt a stable, helical structure, which is important for its function in cell signaling. The C-terminal T-loop domain is responsible for the protein's ability to interact with various protein partners, including other proteins that are involved in the TGF-β pathway.

The function of ARID1B is also unique, as it is involved in the regulation of cell signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and is a key factor in the development and progression of many chronic diseases, including cancer, cardiovascular disease, and neurodegenerative diseases. The regulation of the TGF-β pathway by ARID1B is important for the regulation of cell growth and the maintenance of tissue homeostasis.

Potential Applications

The potential applications of ARID1B as a drug target or biomarker are significant. As a drug target, ARID1B could be targeted with small molecules or antibodies to inhibit its function in the TGF-β pathway, leading to the inhibition of cell signaling and the regression of tissue pathologies. This could be useful for the treatment of chronic diseases such as cancer, cardiovascular disease, and neurodegenerative diseases.

As a biomarker, ARID1B could be used to diagnose and monitor the progression of many diseases. Its expression levels could be used as a diagnostic marker for diseases such as cancer, where increased expression of ARID1B could indicate the presence of cancer cells. Its expression levels could also be used as a biomarker for diseases such as neurodegenerative diseases, where decreased expression of ARID1B could indicate the progression of neurodegeneration.

In conclusion, the structure and function of ARID1B make it an attractive target for drug research and a potential biomarker for the treatment of chronic diseases. Further studies are needed to fully understand its potential as a drug target and biomarker, and to develop effective therapies that can harness its unique properties.

Protein Name: AT-rich Interaction Domain 1B

Functions: Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development a switch from a stem/progenitor to a postmitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to postmitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes (nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth (By similarity). Binds DNA non-specifically (PubMed:14982958, PubMed:15170388)

The "ARID1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARID1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets